Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis.

Daumerie, Chantal;Vynckier, Stefaan;Caussin, Jacques;Jadoul, Michel;Wambersie, André;et.al.
(1996) Thyroid — Vol. 6, n° 4, p. 301-304 (1996)

Files

No attached file found for this publication.

Details

Authors
  • Daumerie, ChantalUCLouvain
    Author
  • Vynckier, StefaanUCLouvain
    Author
  • Caussin, JacquesUCLouvain
    Author
  • Jadoul, MichelUCLouvain
    Author
  • Squifflet, Jean-PaulUCLouvain
    Author
  • Wambersie, AndréUCLouvain
    Author
Show more
Abstract
To deliver optimal radioiodine activity in hemodialyzed patients with thyroid carcinoma, the behavior of radioiodine was followed during six treatments. During hemodialysis, blood activity decreases with a half-life of 3.4 +/- 0.5, (1SD) h. The whole body dose was calculated from the total activity determined during 10 days after 131I administration. A reasonable strategy may consist in delivering 25% of the currently prescribed activity (925 MBq-25 mCi) and to perform the first dialysis session after 24 h to reduce total body irradiation.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Daumerie, C., Vynckier, S., Caussin, J., Jadoul, M., Squifflet, J.-P., De Patoul, N., & Wambersie, A. (1996). Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Thyroid, 6(4), 301-304. https://doi.org/10.1089/thy.1996.6.301 (Original work published 1996)